# EBR Systems, Inc. > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/fi/companies/EBR Systems, Inc.). ## Overview EBR Systems, Inc. develops and commercializes the WiSE CRT System, a leadless cardiac resynchronization therapy platform used to help treat heart failure patients who need pacing support. The company is transitioning from development to U.S. commercialization after FDA approval in April 2025, with its business centered on hospital adoption, reimbursement coverage, and clinical workflow integration. ## Products & services • WiSE CRT System for cardiac resynchronization therapy • Leadless left ventricular endocardial pacing technology • U.S. commercial launch and hospital adoption support • Physician and hospital staff training programs • Regulatory, reimbursement and market-access support - **WiSE CRT System** (100%) — The company's core commercial product for cardiac resynchronization therapy using leadless pacing technology. - WiSE CRT System for cardiac resynchronization therapy - Leadless left ventricular endocardial pacing technology - U.S. commercial launch and hospital adoption support - Physician and hospital staff training programs - Regulatory, reimbursement and market-access support ## Customers EBR sells primarily to hospitals and the physicians who implant and use the WiSE CRT System in cardiac procedures. Adoption depends on electrophysiologists, cath lab teams, and hospital administrators that evaluate clinical utility, workflow fit, and reimbursement coverage before expanding use across sites. - **U.S. hospital customers** (primary) — Hospitals that purchase and use WiSE CRT for approved cardiac procedures, driven by clinical demand and reimbursement coverage. - **Implanting physicians and electrophysiology teams** (primary) — Physicians and clinical teams who decide whether to adopt the technology and how frequently it is used per site. - **International hospital markets** (secondary) — Hospitals in Australia, the United Kingdom and the European Union targeted for future launch once approvals and coverage are in place. - Hospitals performing cardiac resynchronization procedures - Electrophysiologists and implanting physicians - Cath lab and hospital staff needing training and workflow support - Health systems that require reimbursement coverage before adoption - International hospitals in target launch markets after approvals ## Geography The company is currently focused on the United States, where WiSE received FDA approval in April 2025 and commercial launch began in the second quarter of 2025. Outside the U.S., EBR is preparing for future commercialization in Australia, the United Kingdom and the European Union, but those markets depend on regulatory approvals, certification and payment coverage. - United States is the initial commercial market after FDA approval - U.S. reimbursement coverage is critical to adoption and pricing - Australia is a stated target for future OUS launch - United Kingdom is a stated target for future OUS launch - European Union is a stated target for future OUS launch ## Strategy EBR's near-term strategy is to scale U.S. commercialization by expanding the field team, improving hospital training, and increasing implants per site. The company is also pursuing reimbursement coverage and preparing for international expansion, but execution depends on regulatory approvals, clinical adoption and available funding. - **Scale U.S. commercial launch** (short-term) — The company now needs to convert FDA approval into recurring hospital usage and revenue. - **Improve reimbursement and market access** (short-term) — Coverage determines whether hospitals can economically adopt the system at scale. - **Prepare international commercialization** (medium-term) — OUS markets could expand the addressable market once regulatory and payment hurdles are cleared. - Expand the U.S. field team to reach more high-volume sites - Improve training and hospital workflows to raise implants per site - Increase physician awareness and market acceptance of WiSE CRT - Secure reimbursement coverage to support adoption and pricing - Prepare OUS launches in Australia, the UK and the EU ## Risks EBR remains a development-to-commercialization company with substantial going-concern risk and dependence on external financing. Its business is also exposed to regulatory, reimbursement and adoption risk because WiSE is its only FDA-approved product and success depends on hospital uptake, post-marketing compliance and continued access to capital. - **Going concern and financing risk** [critical] — The company expects continued operating losses and negative cash flow, so it may need additional capital to fund commercialization. - **Single-product concentration** [high] — WiSE CRT is the only FDA-approved product, so revenue generation depends on one platform succeeding commercially. - **Reimbursement and market-access risk** [high] — Hospitals may not adopt the system broadly without adequate CMS and payer coverage. - **Regulatory compliance risk** [high] — Post-marketing FDA obligations, cGMP and reporting requirements can drive cost and create withdrawal risk if not met. - **Competitive pressure** [medium] — Large, well-capitalized medtech competitors can outspend EBR on sales, evidence generation and physician engagement. - Going-concern risk if the company cannot raise additional capital - Single-product dependence on WiSE CRT System - Reimbursement uncertainty could limit hospital adoption - FDA post-marketing obligations may create added cost or penalties - Competition from larger medical device companies may pressure adoption ## Accounting EBR's reported results are heavily shaped by development-stage accounting, with losses, stock-based compensation and interest expense still dominating performance. Investors should watch revenue recognition as commercialization begins, the treatment of debt-related interest and any non-cash items tied to financing, as well as estimates around going-concern disclosures and potential impairment if adoption is slower than expected. - **Revenue recognition on WiSE sales** — Affects reported revenue timing and quarterly comparability - **Going-concern assessment** — Signals financing dependence and affects investor interpretation of liquidity - **Stock-based compensation** — Inflates operating expenses and reduces comparability of adjusted metrics - **Debt and interest expense** — Affects net loss and leverage analysis - Revenue recognition will become important as WiSE sales begin - Going-concern disclosure reflects cash runway and financing assumptions - Stock-based compensation affects reported operating loss and EBITDA - Debt interest and financing costs affect net loss - Future commercialization may create inventory, warranty or return estimates --- *Last updated: 2026-04-28T20:02:44.814877+00:00*